Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients

Table 1 Baseline characteristics of subjects in the different groups n (%)

	Non-HBV infected (n = 105)	HBsAg(-)/HBcAb(+) (n = 32)	HBsAg(+) (n = 25)	P value
Gender				0.582
Male	69 (65.71)	22 (68.75)	14 (56)
Female	36 (34.29)	10 (31.25)	11 (44)
Age (yr)	31.35 ± 11.88	32 ± 10.31	32.48 ± 9.66	0.887
Type of disease1				0.576
Acute myeloid leukemia	44 (41.90)	18 (56.25)	15 (60)
Acute lymphoblastic leukemia	30 (28.57)	6 (18.75)	6 (24)
Aplastic anemia	16 (15.24)	4 (12.50)	1 (4)
Others	15 (14.29)	4 (12.50)	3 (12)
Methods of transplantation				0.548
Sibling	80 (76.19)	21(65.63)	20 (80)
Unrelated	21 (20.00)	9 (28.13)	3 (12)
Haploidy	4 (3.81)	2 (6.25)	2 (8)

¹Represented Fisher’s exact tests used. Continuous variables were presented as mean ± SD or median (ranges). Categorical variables were presented as counts and percentages.

Table 2 Complications of subjects in the different groups n (%)

	Non-HBV infected (n = 105)	HBsAg(-)/HBcAb(+) (n = 32)	HBsAg(+) (n = 25)	P value
GVHD
Acute	39 (37.14)	15 (46.88)	10 (40)	0.614
Chronic	41(39.05)	13 (40.63)	10 (40)	0.986
Involvement1				0.366
Extensive	29 (70.73)	10 (76.92)	5 (50)
Limited	12 (29.27)	3 (23.08)	5 (50)
Grade1				0.089
I	2 (5.13)	3 (20)	2 (20)
II	19 (48.72)	2 (13.33)	2 (20)
III	16 (41.03)	7 (46.67)	4 (40)
IV	2 (5.13)	3 (20)	2 (20)
Drug-induced liver injury	27 (25.71)	6 (18.75)	7 (28)	0.717
Organ injury	34 (82.93)	11 (68.75)	9 (90)	0.372
Death	39 (37.14)	13 (40.63)	13 (52)	0.401
Time of granular cells engraftment (d), median (range)	12 (7-35)	12 (9-20)	10 (8-19)	0.091
Time of megakaryocytic cells engraftment (d), median (range)	15 (9-50)	15 (9-49)	15 (9-48)	0.880

¹Represented Fisher’s exact tests used. GVHD: Graft-vs-host disease.